SAB Biotherapeutics Stock (NASDAQ: SABS) stock price, news, charts, stock research, profile.
Open | $2.82 |
Close | $2.93 |
Volume / Avg. | 896.00 / 15.74K |
Day Range | 2.82 - 2.96 |
52 Wk Range | 2.36 - 10.50 |
Market Cap | $25.01M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 46 |
Short Interest | 0.49% |
Days to Cover | 1.83 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of SAB Biotherapeutics (NASDAQ:SABS) through any online brokerage.
Other companies in SAB Biotherapeutics’s space includes: Vincerx Pharma (NASDAQ:VINC), NKGen Biotech (NASDAQ:NKGN), Gain Therapeutics (NASDAQ:GANX), Aligos Therapeutics (NASDAQ:ALGS) and Bolt Biotherapeutics (NASDAQ:BOLT).
There is no analysis for SAB Biotherapeutics.
SAB Biotherapeutics has a consensus price target of $12.40.
The stock price for SAB Biotherapeutics (NASDAQ: SABS) is $2.71 last updated June 21, 2024 at 8:10 AM EDT.
There are no upcoming dividends for SAB Biotherapeutics.
SAB Biotherapeutics’s Q2 earnings are confirmed for Monday, August 19, 2024.
There is no upcoming split for SAB Biotherapeutics.
SAB Biotherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.